- Home | GSK US
Meet Shreya: From hot pink goggles to scientist Shreya shares her journey from when she was a little girl in Science in Summer to having a career at GSK today
- Careers | GSK US
At GSK, we unite science, technology and talent to get ahead of disease together We aim to positively impact the health of 2 5 billion people by the end of the decade, as a successful, growing company where people can thrive
- Vaccines | GSK US
The vaccines in our portfolio have been helping to protect people from serious disease for well over 100 years, with our Marietta, PA site dedicated to smallpox vaccine production since 1882 Today, our vaccines continue to make an impact for society by tackling some of the world’s most devastating diseases, including pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough and
- Products - GSK US
Unfortunately, we cannot provide comprehensive information about our products here, in compliance with regulations If you are a healthcare professional, you can access more product information on our GSKPro website In the US, if you are a patient and have questions about our medicines, please contact the GSK Response Center
- Contact us - GSK
Disaster response - Contact our US Response Center online if you need help accessing your GSK medicines during a natural disaster Patient Assistance Programs - We are committed to helping patients access our medications, and have a long history of providing a range of programs to help them
- Search jobs - GSK US
Life at GSK We are transforming our culture to create an environment where individuals and teams are inspired to be ambitious for patients
- Press releases - GSK US
GSK to invest $30 billion in R D and Manufacturing in the United States over next 5 years New facilities will bridge R D and manufacturing across both the US and UK, strengthening the two countries’ leadership in life sciences
- GSK to invest $30 billion in R D and Manufacturing in the United States . . .
GSK plc (LSE NYSE: GSK) today announced plans to invest $30 billion across the United States in research and development and supply chain infrastructure over the next five years
|